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Abstract: We report the case of an HIV
the spinal cord. The patient received chemotherapy and immunotherapy for Burkitt lymphoma one 
year before. At the time of the diagnosis of toxoplas
and  sulfamethoxazole and in complete remission of Burkitt lymphoma. The CD4+  T cell count was 
270 /l and the  HIV viremia was  undetectable. These findings suggest that in this patient, the 
immunodeficiency  promoting  the  neurologic  toxoplasmosis  arose  more  from  previous  immuno
chemotherapy than from the HIV
stratification for opportunistic infections of HIV
previous medical history and therapies received. 
Introduction. Common  anticancer  therapies  are 
associated  with  hematological  toxicity  and 
immunological impairment. In particular, patients with 
lymphomas  may  cope  with  a  wide  spectrum  of 
infectious  complications.  In  this  respect,  individuals 
with  HIV-related  lymphomas  represent  a  subset  of 
patients  at  high  risk  for  various  kinds  of  infections. 
Furthermore,  several  infectious  diseases    can  induce 
similar symptoms or imaging pictures as lymphomas. 
As a consequence,  the differential diagnosis  between 
the  lymphoma  and  the  infection  arising  from  the 
immunologic  deficiency   can be sometimes difficult.  
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We report the case of an HIV-infected young men with neuro-toxoplasmosis localized in 
the spinal cord. The patient received chemotherapy and immunotherapy for Burkitt lymphoma one 
year before. At the time of the diagnosis of toxoplasmosis, he was on prophylaxis with trimethoprim 
and  sulfamethoxazole and in complete remission of Burkitt lymphoma. The CD4+  T cell count was 
was  undetectable. These findings suggest that in this patient, the 
immunodeficiency  promoting  the  neurologic  toxoplasmosis  arose  more  from  previous  immuno
chemotherapy than from the HIV- infection itself. On the whole, this case highlights that the risk 
stratification for opportunistic infections of HIV-infected patients should carefully consider their 
previous medical history and therapies received. 
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neuro-toxoplasmosis  when  he  was  in  complete 
lymphoma remission, despite the CD4
recovery  and  the  trimethoprim/  sulfamethoxazole 
prophylaxis.  
Case report. A 44-year-old man was admitted to the 
infectious disease department of our hospital for fever 
and  abdominal  distension.  The  CT
6.5  cm  abdominal  lymph  node  mass  with  peritoneal 
infiltration. Patient was found HIV
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the spinal cord. The patient received chemotherapy and immunotherapy for Burkitt lymphoma one 
mosis, he was on prophylaxis with trimethoprim 
and  sulfamethoxazole and in complete remission of Burkitt lymphoma. The CD4+  T cell count was 
was  undetectable. These findings suggest that in this patient, the 
immunodeficiency  promoting  the  neurologic  toxoplasmosis  arose  more  from  previous  immuno-
infection itself. On the whole, this case highlights that the risk 
infected patients should carefully consider their 
Here we describe the case of an HIV-positive men with 
a  concomitant  Burkitt  lymphoma,  who  developed  
toxoplasmosis  when  he  was  in  complete 
lymphoma remission, despite the CD4+ T cell count 
recovery  and  the  trimethoprim/  sulfamethoxazole 
old man was admitted to the 
infectious disease department of our hospital for fever 
and  abdominal  distension.  The  CT-scan  evidenced  a 
6.5  cm  abdominal  lymph  node  mass  with  peritoneal 
infiltration. Patient was found HIV-1 infected and the Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
CT driven lymph node biopsy led to the diagnosis of 
Burkitt lymphoma.  At  that  time, CD4+ T  cell count 
was 55 /l,  HIV-RNA copies  were 232.000 /ml and 
patient was proven positive for anti-Toxoplasma IgG 
antibodies.  Combined  antiviral  therapy  (cART)  with  
emtricitabine /tenofovir/ lopinavir and prophylaxis for 
Toxoplasmosis/ Pneumocystis jiroveci pneumonia and 
disseminated  Mycobacterium  Avium  Complex 
infection  with  trimethoprim/  sulfamethoxazole  and 
azithromycin at standard doses were undertaken. In the 
meanwhile,  patient  underwent  chemotherapy  for 
Burkitt lymphoma, according to the Magrath protocol, 
consisting  of  the  administration  of  two  regimens: 
CODOX-M (Cyclophosphamide 800 mg/m
2 i.v.day 1; 
Vincristine  1.5  mg/m
2 i.v.  days  1,  8  and  15; 
Doxorubicin 40 mg/m2 i.v. day 1,  Cytarabine 70 mg 
i.t.  days  1  and  3;  Cyclophosphamide  200  mg/m
2
i.v.days 2–5; Methotrexate 1200 mg/m
2 i.v. over 1 hour 
and  then 240 mg/m
2 i.v. each hour over 23 hours, day 
10; Leucovorin 192 mg/m
2 i.v. day 11 at hour 36 after 
methotrexate  and  then  12  mg/m
2 i.v.  every  6  hours  
until  methotrexate  level  was  not  detectable;  
Methotrexate 12 mg i.t. day 15) and IVAC (Ifosfamide 
1500 mg/ m
2 i.v. days 1-5; Mesna 360 mg/m
2 mixed 
with ifosfamide  i.v. and  then 360 mg/m
2 i.v. 3 hourly 
for  seven  doses,  Etoposide  60  mg/  m
2  i.v.  days 1-5, 
Cytarabine  2  g/m
2 i.v.  12  hourly  for  a  total  of  four 
doses, days 1-2,  Methotrexate 12 mg i.t.day 5)
1. G-
CSF was administered at dose of 5 µg/kg s.c. daily,  
from day 15 after CODOX-M  and  from day 7 after 
IVAC    regimen,    until neutrophil  granulocyte  count 
reached  0,5 × 10
9/l.  Overall, the patient received two 
alternating  CODOX-M/IVAC  courses  and  four  
Rituximab administrations at 375 µg/ m
2 i.v. dose over 
a six month period. A total body  CT scan performed at 
the end of therapy, showed normal lymph node,  liver 
and  spleen  size.  The  complete  remission  of  the 
lymphoma was subsequently confirmed by a 18-FDG-
PET scan. The CD4+ T cell count arose progressively 
to  normal  values   and the HIV-RNA  copies  became 
persistently undetectable. Four months after the end of 
the therapy, the patient started to complain progressive 
weakness  of  legs,  and,  afterwards,  sudden  urinary 
retention.  He  was  still  on  prophylaxis  with 
trimethoprim/sulfamethoxazole  without  interruption; 
CD4+  T cell count was 270 /l and HIV-RNA was 
undetectable (< 50 copies/ml). Neurologic examination 
revealed absent ankle reflexes, reduced strength (3/5) 
in lower limbs and saddle sensory deficit. The spine 
MRI  with  Gadolinium  showed  a  focal  lesion  of  the 
conus medullaris, involving the proximal portion of the 
cauda equina nerve roots. The lesion was hyper-intense 
on T2-weighted images and showed marked contrast-
enhancement (Figure 1a-c, white arrows). The patient 
was then admitted to our department: the brain MRI 
demonstrated  an  additional  lesion  in  the  deep  right 
frontal region (0.5 cm), with signal alterations similar 
to  that  of  the  spinal  cord.  The  cerebral  spinal  fluid 
(CSF) examination showed a slight increase of protein 
and  cell  concentrations  (199  mg/dl  and  56/mm
3, 
respectively), with any evidence of immature lymphoid 
cells.  The  flow  cytometry  analysis  of  CSF  samples 
revealed that cells were CD19 positive B lymphocytes,  
without  or  light chain restriction. PCR assays for 
Mycobacterium tuberculosis-DNA, Epstein Barr virus 
(EBV)-DNA and cytomegalovirus -DNA on CSF were 
all negative. The search for Cryptococcus antigen was 
negative,  as  well.  Whereas  both  brain  and  spinal 
lesions  were  highly  suggestive  for  lymphoma 
localizations, the total body CT scan showed no liver, 
spleen or lymph node enlargement consistent with the 
systemic relapse of the Burkitt lymphoma. Indeed, in 
the suspicion of an isolated CNS relapse, the patient 
underwent open biopsy of the conus medullaris lesion. 
The  histological  examination  revealed  numerous 
Toxoplasma  tachyzoites  surrounded  by  inflammatory 
cells (Figure 1d). Actually, the patient referred that he 
owned a cat who lived with him. Indeed, the proper 
treatment  with  pyrimethamine  and  sulfadiazine  was 
undertook    with  marked  improvement  of  neurologic 
conditions in few weeks. The patient showed the full 
neurologic recovery and the MRI scan performed after 
4 months demonstrated the definite disappearance of 
both spinal and brain lesions.  
Discussion. This case underscores how the detection of 
spinal  cord  enhancing  lesion  in  AIDS  patients 
represents a diagnostic challenge. In particular, in this 
patient, the pre-existing diagnosis of Burkitt lymphoma 
and the unusual inaugural spinal cord localization of
toxoplasmosis undoubtedly hampered the diagnosis of 
neuro-toxoplasmosis.    Actually,  especially  in  HIV-
infected people, Burkitt lymphoma exhibits a marked 
CNS  tropism,
1 while  spinal  cord  toxoplasmosis  has 
been  rarely  reported.  Vyas  and  Ebright  described 
fourteen  cases  of  spinalMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. Spine MRI with Gadolinium . The lesion of the conus medullaris  involving the proximal portion of cauda equina nerve roots (a), 
was  hyper-intense  on  T2-weighted  images  (b)  and  showed  marked  contrast-enhancement  (c).  Histological  examination  of  the  conus 
medullaris biopsy (d) (Hematoxiline eosin staining).
cord toxoplasmosis in AIDS patients;  afterwards, one 
additional case has been recently reported.
4 Eleven out 
of  these  15  patients  showed  also  brain  lesions: 
importantly, the mortality rate in this series of patients 
is  40  %  (6  out  of  15  patients).
3 However,  in  our 
opinion, the case here  reported is remarkable because 
of  neurologic toxoplasmosis  occurred in  spite of  the 
proper  prophylaxis  and  with  a  CD4+    T  cell  count 
higher  than  200  /l.  Actually,  toxoplasma  causes 
encephalitis mainly in severely immune-compromised 
patients,  or  in  those  not  receiving  primary 
prophylaxis.
3 In contrast,  immuno-recovered patients 
are  considered at low  risk for  this complication, so 
that,  in  this  subset  of  patients,  the  interruption  of  
prophylaxis has been recently proposed.
6 Interestingly, 
a case of solitary spinal cord toxoplasmosis has been 
reported  by  Straathof  in  an  HIV-negative  patient 
undergoing  autologous  stem-cell  transplantation  for 
multiple  myeloma.
7 Actually,  in  the  setting  of 
hematological  patients  receiving  high  dose 
chemotherapy, cerebral toxoplasmosis constitutes one 
of  the  most  frequent  neurologic  complication  and  is Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
associated with a high mortality rate.
6 Similarly, our 
patient  received  intensive  chemotherapy  and 
immunotherapy  for  Burkitt  lymphoma,  probably 
resulting in the persistent dysfunction of cell-mediated 
immunity despite the adequate lymphocyte count. 
The  cART  dramatically  reduced the  incidence  of 
CNS opportunistic infections in HIV-infected people; 
in  addition,  its  association  with  intensive 
chemotherapies  significantly  improved  the  prognosis 
of patients with HIV- related lymphomas. Nonetheless, 
chemotherapy  and  immunotherapy  related  toxicities 
resulted  in  a  wide  spectrum  of  infectious 
complications. Importantly,  this case highlights how 
the    CD4+  T  cell  count  and  the  HIV  RNA  are  not 
suitable  tools  to  predict  the  risk  of  opportunistic 
infections in HIV-infected people  with lymphomas.
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